NTAIYY consistently produced the desired therapeutic effects on a series of cancer cell lines harboring wild-type p53, including MCF7 and MDA-MB-231 (breast), HCT116 (colon), HT29 (colorectal), A549 and H2087 (lung), and Capan-2 and HPAC (PDAC). Here, TP53 is linked to cancer.